Breaking News

The near-term outlook for pharma earnings; an unlikely crusader winning the fight on hospital prices

 

Pharmalot Ed Silverman

STAT+: The near-term outlook for pharma industry earnings just got a little worse

By Ed Silverman

APStock

The primary driver for the change in outlook by Moody’s Investor Service is concern about looming patent expirations.

Read More

The unlikely crusader who's winning the fight to lower hospital prices

By Rachel Cohrs

Adobe

Al Hubbard has been driving a remarkably successful campaign to lower extraordinarily high hospital prices in Indiana.

Read More

Democrats tweak their drug pricing plan in last-ditch effort to pass reforms

By Rachel Cohrs

J. Scott Applewhite/AP Photo

Senate Democrats are vetting a new, tweaked version of a drug pricing package as they hurtle toward a September deadline to pass reforms.

Read More

STAT+: New analysis of Amarin's Vascepa resurrects big questions about effectiveness

By Matthew Herper

Adobe

Some experts say the questions require a new clinical trial to be run, and some even say the FDA should reconsider the product’s approval.

Read More

Listen: Medical privacy post-Roe, fixing clinical trials, & the next Covid vaccines

By Damian Garde and Meg Tirrell and Adam Feuerstein

This week, our colleague Eric Boodman joins us to discuss whether HIPAA can shield reproductive health data from state law enforcement.

Read More

Thursday, June 30, 2022

STAT

Facebook   Twitter   YouTube   Instagram

1 Exchange Pl, Suite 201, Boston, MA 02109
©2022, All Rights Reserved.
I no longer wish to receive STAT emails
Update Email Preferences | Contact Us | View In Browser

No comments